Rosetta Genomics said this week that it has signed definitive agreements to sell an aggregate of $6 million in securities in concurrent private placement and registered direct offerings.
In the private placement, Rosetta will sell roughly 4.5 million ordinary shares at $0.60 each. Purchasers of the stock will also receive warrants to buy up to about 3.4 million more shares at $0.80 apiece.
In the direct offering, the company will sell approximately 5.5 million shares at $0.60 a share. Purchasers will also receive warrants to buy up to 2.7 million more shares at $0.80 per share.
Closing of the offerings is expected to occur around the end of February.